MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: STEMCELL Technologies, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

STEMCELL Technologies Signs Exclusive Agreement with the Institute of Molecular Biotechnology to Commercialize Cerebral Organoid Culture Systems - STEMCELL Technologies has entered into an exclusive licensing agreement with the Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences
STEMCELL Technologies Signs Exclusive Agreement with the Institute of Molecular Biotechnology to Commercialize Cerebral Organoid Culture Systems

 

NewswireToday - /newswire/ - Vancouver, British Columbia, Canada, 2016/04/13 - STEMCELL Technologies has entered into an exclusive licensing agreement with the Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

STEMCELL Technologies has entered into an exclusive licensing agreement with the Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences for the rights to develop products for cerebral organoid culture to serve the international research community.

Cerebral organoids, or brain organoids, are three-dimensional multicellular structures that mimic brain tissue in vitro and represent a groundbreaking new way to model neurological disease. Deriving cerebral organoids from patient-specific induced pluripotent stem cells enables unprecedented insight into mechanisms of human neural development and disease. Madeline Lancaster and Jürgen Knoblich developed a cerebral organoid culture system, published in Nature (M. Lancaster et al. 2013), that is rapidly being adopted by researchers worldwide.

“These ‘mini brains’ resemble the early steps of human embryonic brain development, making them excellent model systems,” says Knoblich, Deputy Scientific Director of IMBA. “We’ve already been able to model microcephaly with the cerebral organoids and hope that by making this technology available, we’ll enable scientists from across the globe to develop other models for neurological diseases and disorders.”

Dr. Allen Eaves, CEO and President of STEMCELL Technologies stated that “we are pleased to have entered into an agreement with IMBA to develop products to support one of the most exciting new fields of scientific research. With this technology, there finally exists an in vitro culture system that gives us a glimpse into the complexities of the human brain, undoubtedly improving our understanding of brain development and neurological diseases.”

Commenting on the agreement, the Managing Director of IMBA, Michael Krebs stated that “IMBA is very excited to work with STEMCELL Technologies and contribute to its ambitions to build up a portfolio of products in the emerging field of organoid technologies”. Based on its patented organoid technology, IMBA is currently developing different disease models for neuronal disorders for use in customized drug-screening and/or target validation applications.

The products for cerebral organoid culture arising from this agreement will complement STEMCELL’s extensive portfolio of products for neural cell culture applications, including the NeuroCult™ and STEMdiff™ product lines, together with the new BrainPhys™ Neuronal Medium. All products are developed and manufactured using STEMCELL Technologies’ rigorous raw material screening and quality control processes.

STEMCELL Contact: Benjamin Thiede, Business Development Officer
P: 604-675-7865 - E: benjamin.thiede[.]stemcell.com.

IMBA Contacts:
Jürgen Knoblich, Deputy Scientific Director
P: +43 1 79044 - 4800 -E: juergen.knoblich[.]imba.oeaw.ac.at.

Michael Krebs, Managing Director
P: +43 1 79044 - 4400 - E: michael.krebs[.]imba.oeaw.ac.at.

About STEMCELL Technologies
As Scientists Helping Scientists, STEMCELL Technologies (stemcell.com) is committed to providing high-quality cell culture media, cell isolation products and accessory reagents for life science research. Our specialty cell culture reagents, instruments and tools are designed to support science along the basic to translational research continuum. To learn more, visit STEMCELL Technologies.

About IMBA - Institute of Molecular Biotechnology
IMBA - Institute of Molecular Biotechnology (IMBA) is one of the leading biomedical research institutes in Europe focusing on cutting-edge functional genomics and stem cell technologies. IMBA (imba.oeaw.ac.at) is located at the Vienna Biocenter, the vibrant cluster of universities, research institutes and biotech companies in Austria. IMBA is a subsidiary of the Austrian Academy of Sciences, the leading national sponsor of non-university academic research.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: STEMCELL Technologies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


STEMCELL Technologies Signs Exclusive Agreement with the Institute of Molecular Biotechnology to Commercialize Cerebral Organoid Culture Systems

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Sam Lloyd-Burton - Stemcell.com 
604-675-7888 sam.lloyd-burton[.]stemcell.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any STEMCELL Technologies, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From STEMCELL Technologies, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  Limelon Advertising, Co.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)